Edgewise Therapeutics, Inc. Payments to Acquire Marketable Securities
Edgewise Therapeutics, Inc. (EWTX) reported Payments to Acquire Marketable Securities of $163.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- Edgewise Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $53.09M, a 79.87% decline year-over-year.
- Edgewise Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $110.15M, a 9.84% decline year-over-year.
- Edgewise Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $74.28M, a 17.58% increase year-over-year.
- Edgewise Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $67.00M, a 47.84% increase year-over-year.
- Edgewise Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $527.23M, a 10.52% increase from fiscal 2024.
- Edgewise Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $477.06M, a 86.45% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $255.87M, a 12.49% decline from fiscal 2022.
- Edgewise Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $292.39M, a 1.45% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $53.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $163.24M 10-Q · filed 2026-08-06 | $237.52M derived: sum of 3 quarters · filed 2026-08-06 | $304.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $110.15M 10-Q · filed 2026-05-07 | $184.44M derived: sum of 2 quarters · filed 2026-05-07 | $251.44M derived: sum of 3 quarters · filed 2026-05-07 | $515.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $74.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $141.28M derived: sum of 2 quarters · filed 2026-02-26 | $405.05M derived: sum of 3 quarters · filed 2026-08-06 | $527.23M 10-K · filed 2026-02-26 |
| 2025-09-30 | $67.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $330.76M derived: sum of 2 quarters · filed 2026-08-06 | $452.94M 10-Q · filed 2025-11-06 | $516.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $263.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $385.94M 10-Q · filed 2026-08-06 | $449.12M derived: sum of 3 quarters · filed 2026-08-06 | $494.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $122.18M 10-Q · filed 2026-05-07 | $185.36M derived: sum of 2 quarters · filed 2026-05-07 | $230.68M derived: sum of 3 quarters · filed 2026-05-07 | $271.63M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $63.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $108.50M derived: sum of 2 quarters · filed 2026-02-26 | $149.45M derived: sum of 3 quarters · filed 2026-02-26 | $477.06M 10-K · filed 2026-02-26 |
| 2024-09-30 | $45.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $86.27M derived: sum of 2 quarters · filed 2025-11-06 | $413.88M 10-Q · filed 2025-11-06 | $453.66M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $40.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $368.56M 10-Q · filed 2025-08-07 | $408.34M derived: sum of 3 quarters · filed 2026-02-26 | $493.01M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $327.60M 10-Q · filed 2025-05-08 | $367.39M derived: sum of 2 quarters · filed 2026-02-26 | $452.06M derived: sum of 3 quarters · filed 2026-02-26 | $566.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $39.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $124.45M derived: sum of 2 quarters · filed 2026-02-26 | $238.91M derived: sum of 3 quarters · filed 2026-02-26 | $255.87M 10-K · filed 2026-02-26 |
| 2023-09-30 | $84.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $199.12M derived: sum of 2 quarters · filed 2024-11-07 | $216.08M 10-Q · filed 2024-11-07 | $362.77M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $114.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $131.41M 10-Q · filed 2024-08-08 | $278.10M derived: sum of 3 quarters · filed 2024-08-08 | $346.09M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $16.96M 10-Q · filed 2024-05-09 | $163.65M derived: sum of 2 quarters · filed 2024-05-09 | $231.64M derived: sum of 3 quarters · filed 2024-05-09 | $295.39M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $146.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $214.68M derived: sum of 2 quarters · filed 2024-02-22 | $278.43M derived: sum of 3 quarters · filed 2024-02-22 | $292.39M 10-K · filed 2024-02-22 |
| 2022-09-30 | $67.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $131.74M derived: sum of 2 quarters · filed 2023-11-09 | $145.70M 10-Q · filed 2023-11-09 | $160.74M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $63.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $77.71M 10-Q · filed 2023-08-10 | $92.75M derived: sum of 3 quarters · filed 2023-08-10 | $134.11M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $13.96M 10-Q · filed 2023-05-11 | $29.00M derived: sum of 2 quarters · filed 2023-05-11 | $70.36M derived: sum of 3 quarters · filed 2023-05-11 | $237.45M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $15.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $56.40M derived: sum of 2 quarters · filed 2023-02-23 | $223.49M derived: sum of 3 quarters · filed 2023-02-23 | $288.20M 10-K · filed 2023-02-23 |
| 2021-09-30 | $41.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $208.45M derived: sum of 2 quarters · filed 2022-11-03 | $273.16M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $167.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $231.80M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $64.71M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $24.18M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |